Update: Oncology Pharma Signed a Letter of Intent with Kalos Therapeutics for an Exclusive World-Wide License and Co-Development of Its Broad-Spectrum Anti-Cancer Drug, KTH 222

Daniel Sontupe
Market Access

Matthew Durham
Omnidynamic Marketing

Frank Burrell
Scientific Storytelling

Pat Purcell
Meeting Engagement

Liz Kane
Impactful Strategy

Matt Turner
Patient Affordability

Paul Theisen
Patient Acquisition

Joey Cohen
Medication Adherence

Stacey Gandler
Brand Nourishment

Suma Ramadas, PhD
Medical Affairs

Bud Bilanich
Success Coach

David Linetsky
Point-of-Care Marketing

Amy Giles
Increasing Engagement

Brenda Snow
Authentic Patient Voice